Abstracts tagged "Psoriatic arthritis"

Abstract Number: 930 • 2016 ACR/ARHP Annual Meeting
How to Implement Cardiovascular Disease Risk Assessment for Patients with Inflammatory Joint Diseases in Daily Rheumatology Practice: An Overview of a Nationwide Norwegian Project
Eirik Ikdahl¹, Silvia Rollefstad², Grunde Wibetoe³, Anne Salberg⁴, Dag Magnar Soldal⁵, Inge C Olsen⁶, Tore K Kvien⁶, Glenn Haugeberg⁷ and Anne Grete Semb¹, ¹Preventive Cardio-Rheuma clinic, Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ²Preventive Cardio-Rheuma Clinic, Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ³Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁴Hospital for Rheumatic Diseases, Lillehammer, Norway, ⁵Rheumatology, Hospital of Southern Norway, Kristiansand, Norway, ⁶Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁷Martina Hansens Hospital, Bærum, Norway
Background/Purpose: The EULAR recommendations for cardiovascular disease (CVD) risk management in patients with inflammatory joint diseases (IJD) states that CVD risk assessment should be considered…
Abstract Number: 1713 • 2016 ACR/ARHP Annual Meeting
Long-Term (156-Week) Safety Profile of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis: Pooled Safety Analysis of 3 Phase III, Randomized, Controlled Trials
Philip J Mease¹, Dafna D Gladman², Juan J Gomez-Reino³, Stephen Hall⁴, Arthur Kavanaugh⁵, Eric Lespessailles⁶, Georg Schett⁷, Kamal Shah⁸, Lichen Teng⁸ and Jürgen Wollenhaupt⁹, ¹Swedish Medical Center and University of Washington School of Medicine, Seattle, WA, ²Toronto Western Research Institute, Toronto, ON, Canada, ³Hospital Clinico Universitario, Santiago, Spain, ⁴Monash University, CabriniHealth, Melbourne, Australia, ⁵University of California, San Diego, School of Medicine, La Jolla, CA, ⁶University of Orléans, Orléans, France, ⁷University of Erlangen-Nuremberg, Erlangen, Germany, ⁸Celgene Corporation, Summit, NJ, ⁹Schön Klinik Hamburg-Eilbek, Hamburg, Germany
Background/Purpose: Apremilast (APR), an oral phosphodiesterase 4 inhibitor, acts to regulate immune activity in psoriatic arthritis (PsA) patients. PALACE 1 (NCT01172938), 2 (NCT01212757), and 3…
Abstract Number: 3085 • 2016 ACR/ARHP Annual Meeting
Do Depression and Anxiety Reduce the Chance of Remission in Rheumatoid Arthritis and Psoriatic Arthritis?
Brigitte Michelsen^1,2, Karen M Fagerli¹, Elisabeth Lie¹, Hilde Berner Hammer³, Glenn Haugeberg^4,5, Eirik K Kristianslund¹ and Tore K. Kvien¹, ¹Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ²Dept. of Rheumatology, Hospital of Southern Norway Trust, Kristiansand, Norway, ³Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁴Dept. of Rheumatology, Martina Hansens Hospital, Bærum, Norway, ⁵Dept. of Rheumatology, The Norwegian University of Science and Technology, Trondheim, Norway
Background/Purpose: Depression and anxiety are reported to predict poorer treatment outcomes in rheumatoid arthritis (RA).1 Whether this can be confirmed in larger, prospective studies as…
Abstract Number: 938 • 2016 ACR/ARHP Annual Meeting
Prevalence of Non-Radiographic Axial Spondyloarthritis in Psoriatic Arthritis – a Single Center Observational Study
Victoria Furer¹, Moshe Stark², Hagit Matz³, David Levartovsky⁴, Jonathan Wallman⁵, Irena Wigler⁶, Hagit Sarvagyl-Maman⁷, Ofir Elalouf⁸, Sara Borok Lev-Ran⁹, Daphna Paran⁶, Gideon Flusser¹⁰, Iddo Drukman¹⁰, Iris Eshed¹¹ and Ori Elkayam¹², ¹Rheumatology, Tel Aviv Sourasky Medical Center, The Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel, ²Tel Aviv Medical Center, Tel Aviv, Tel Aviv, Israel, ³Dermatology, Tel Aviv Medical Center, Tel Aviv, Israel, ⁴Rheumatology, Tel-Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel, ⁵Rheumatology, Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel, ⁶Rheumatology, Tel Aviv Sourasky Medical Center and the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel, ⁷Tel Aviv Sourasky Medical Center and the Sackler Faculty of Medicine, Tel Aviv University, Tel-aviv, Israel, ⁸Rheumatology, Tel Aviv Medical Center and the Sackler Faculty of Medicine, Tel Aviv University, Tel-Aviv, Israel, ⁹Tel Aviv Sourasky Medical Center and the Sackler Faculty of Medicine,Tel Aviv University, Tel AViv, Israel, ¹⁰Radiology, Tel Aviv Medical Center, Tel Aviv, Israel, ¹¹Department of Radiology, Sheba Medical Center, Israel, Tel Hashomer, Israel, ¹²Rheumatology, Tel Aviv Medical Center, Tel Aviv, Israel
Background/Purpose: Sacroiliitis, as detected by plain radiographs of the sacroiliac joints (SIJ), has been reported in a third of the psoriatic arthritis (PsA) population. (1)…
Abstract Number: 1722 • 2016 ACR/ARHP Annual Meeting
Predictors of Achieving Remission Among Patients with Psoriatic Arthritis Prescribed TNF Inhibitors
Alexis Ogdie¹, J. Lynn Palmer², Jeffrey D. Greenberg³, Leslie R. Harrold⁴, Daniel H. Solomon⁵, Arthur Kavanaugh⁶, Joel Kremer⁷, Philip J Mease⁸ and Jeffrey R. Curtis⁹, ¹Medicine/Rheumatology and Epidemiology, University of Pennsylvania, Philadelphia, PA, ²Corrona Research Foundation, Albany, NY, ³New York University School of Medicine, New York, NY, ⁴University of Massachusetts Medical School, Worcester, MA, ⁵Division of Rheumatology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁶University of California San Diego, La Jolla, CA, ⁷The Center for Rheumatology, Albany Medical College, Albany, NY, ⁸Rheumatology and Internal Medicine, Swedish Medical Center and University of Washington, Seattle, WA, ⁹Division Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Psoriatic arthritis (PsA) is a heterogeneous disease with varied response to therapy. We examined predictors of remission at one year among patients with PsA…
Abstract Number: 961 • 2016 ACR/ARHP Annual Meeting
Secukinumab Provides Sustained Improvements in the Signs and Symptoms of Active Psoriatic Arthritis through 3 Years: Efficacy and Safety Results from a Phase 3 Trial
Philip J Mease¹, Arthur Kavanaugh², Andreas Reimold³, Hasan Tahir⁴, Juergen Rech⁵, Stephen Hall⁶, Piet Geusens^7,8, Pellet Pascale⁹, Evie Maria Delicha¹⁰, Luminita Pricop¹¹ and Shephard Mpofu¹⁰, ¹Swedish Medical Center and University of Washington, Seattle, WA, ²UC San Diego School of Medicine, La Jolla, CA, ³Dallas VA Medical Center and University of Texas Southwestern Medical Center, Dallas, TX, ⁴Barts Health NHS Trust, London, United Kingdom, ⁵Department of Internal Medicine 3 – Rheumatology and Immunology, Universitätsklinikum Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), Erlangen, Germany, ⁶Monash University, Melbourne, Australia, ⁷University of Hasselt, Hasselt, Belgium, ⁸Maastricht University Hospital, Maastricht, Netherlands, ⁹Novartis Pharma AG, basel, Switzerland, ¹⁰Novartis Pharma AG, Basel, Switzerland, ¹¹Novartis Pharmaceuticals Corporation, East Hanover, NJ
Background/Purpose: Secukinumab, an anti–interleukin-17A monoclonal antibody, provided rapid and significant improvements in the key clinical domains of psoriatic arthritis (PsA) in the FUTURE 1 study…
Abstract Number: 1728 • 2016 ACR/ARHP Annual Meeting
Comparison of Adherence to Disease Modifying Antirheumatic Drugs in Psoriatic Arthritis and Other Rheumatic Disease
Mehmet Ali Balci¹, Mustafa Ferhat Oksuz², Salim Donmez¹, Tugce Ozen³, Ediz Dalkilic², Ayse Nur Tufan², Yavuz Pehlivan² and Omer Nuri Pamuk⁴, ¹Rheumatology, Trakya University Medical Faculty, Edirne, Turkey, ²Rheumatology, Uludag University Medcal Faculty, Bursa, Turkey, ³PHYSICAL THERAPY AND REHABILITATION, Trakya University Faculty of Health Sciences, Edirne, Turkey, ⁴Rheumatology, Department of Rheumatology, Trakya University Medical Faculty, Edirne, Turkey, Edirne, Turkey
Background/Purpose: Psoriatic arthritis (PsA), Rheumatoid arthritis (RA) and ankylosing spondylitis (AS) are an inflammatory arthritis causing joint damage and disability. Non-adherence to disease modifying anti-rheumatic…
Abstract Number: 1326 • 2016 ACR/ARHP Annual Meeting
Autoimmune Arthritides, Rheumatoid Arthritis, Psoriatic Arthritis, or Peripheral Spondyloarthropathy, Following Lyme Disease
Sheila Arvikar¹, Jameson Crowley¹, Katherine Sulka² and Allen C. Steere³, ¹Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Charlestown, MA, ²Rheumatology Allergy and Immunology, Massachusetts General Hospital, Charlestown, MA, ³Center for Immunolgy and Inflammatory Diseases, Massachusetts General Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Lyme arthritis (LA) usually responds to antibiotic therapy, though immune-mediated synovitis may persist after antibiotic treatment, usually confined to a previously infected joint,…
Abstract Number: 1729 • 2016 ACR/ARHP Annual Meeting
Secukinumab for the Treatment of Psoriatic Arthritis: Comparative Effectiveness Versus Infliximab Using a Matching-Adjusted Indirect Comparison
Vibeke Strand¹, Philip J Mease², Iain B McInnes³, Peter Nash⁴, Howard Thom⁵, Matthias Hunger⁶, Kunal Gandhi⁷, Shephard Mpofu⁸ and Steffen Jugl⁸, ¹Stanford University School of Medicine, Palo Alto, CA, ²Swedish Medical Center and University of Washington, Seattle, WA, ³University of Glasgow, Glasgow, United Kingdom, ⁴Department of Medicine, University of Queensland, Brisbane, QLD, Australia, ⁵University of Bristol, Bristol, United Kingdom, ⁶MAPI Group, Munich, Germany, ⁷Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁸Novartis Pharma AG, Basel, Switzerland
Background/Purpose: Secukinumab (SEC) and infliximab (INF) are approved for the treatment of active PsA in adults with an inadequate response to conventional DMARDs. There are…
Abstract Number: 1422 • 2016 ACR/ARHP Annual Meeting
Identifying Generic and Specific Patients’ Perspectives on Disease- and Treatment-Related Issues in Rheumatoid Arthritis, Psoriatic Arthritis, and Psoriasis: A Qualitative Concept Mapping Study
Tanja Schjødt Jørgensen¹, Louise Klokker¹, Henrik Gudbergsen², Simon Francis Thomsen³, Robin Christensen⁴, Henning Bliddal¹ and Lars Erik Kristensen¹, ¹The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Copenhagen, Denmark, ²The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg,, Copenhagen, Denmark, ³Department of Dermatology, Bispebjerg Hospital & Department of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark, ⁴Musculoskeletal Statistics Unit, The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Copenhagen, Denmark
Identifying generic and specific patients’ perspectives on disease- and treatment-related issues in rheumatoid arthritis, psoriatic arthritis, and psoriasis: a qualitative concept mapping studyT.S. Jørgensen1, L.…
Abstract Number: 1731 • 2016 ACR/ARHP Annual Meeting
Disease Burden and Impact of Certolizumab Pegol Treatment on Workplace and Household Productivity Across Working Age Rheumatoid Arthritis, Psoriatic Arthritis and Axial Spondyloarthritis Patients
Arthur F. Kavanaugh¹, Philip J. Mease², Oana Purcaru³ and Désirée van der Heijde⁴, ¹Division of Rheumatology, Allergy, and Immunology, UC San Diego School of Medicine, La Jolla, CA, ²Swedish Medical Center and University of Washington, Seattle, WA, ³208 Bath Road, UCB Pharma, Slough, United Kingdom, ⁴Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Inflammatory diseases such as rheumatoid arthritis (RA), psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA), including ankylosing spondylitis (AS) and non-radiographic axSpA (nr-axSpA), can impact…
Abstract Number: 1423 • 2016 ACR/ARHP Annual Meeting
Using Self-Reported Patient Experiences to Evaluate Patient Reported Outcomes (PRO) Instruments: Learnings from Digital Patient Communities in Psoriatic Arthritis
Stephen Doogan¹, John Heid², Samir Benosman³, Alexis Ogdie⁴, Layne Martin⁵, Prashanth Sunkureddi⁶ and Jacqueline Palmer⁷, ¹Real Life Sciences, New York, NY, ²Kinapse, Inc, London, United Kingdom, ³Advisory Services, Kinapse, Inc, London, United Kingdom, ⁴University of Pennsylvania, Philadelphia, PA, ⁵CreakyJoints, NY, ⁶Rheumatology, Clear Lake Rheumatology Center, Nassau Bay, TX, ⁷Novartis Pharmaceuticals Corporation, East Hanover, NJ
Background/Purpose: Psoriatic Arthritis (PsA) is a debilitating disease with significant impact on patient quality of life (QoL). While patient reported outcome (PRO) instruments broadly capture…
Abstract Number: 1733 • 2016 ACR/ARHP Annual Meeting
Sustained Efficacy of Ixekizumab in Patients with Moderate-to-Severe Plaque Psoriasis and Concomitant Psoriatic Arthritis
Kim Papp¹, Alice B. Gottlieb², Catherine L. Shuler³, Russel T. Burge³, Gregory Cameron³, Lisa Kerr³ and Philip J Mease⁴, ¹K Papp Clinical Research, Inc. and Probity Medical Research, Waterloo, ON, Canada, ²Tufts University School of Medicine, Boston, MA, ³Eli Lilly and Company, Indianapolis, IN, ⁴Rheumatology Research, Swedish Medical Center and University of Washington, Seattle, WA
Background/Purpose: PsA, a chronic immune-mediated inflammatory disease, can be progressive and destructive, resulting in physical deformities, impaired function, decreased quality of life, and increased mortality.…
Abstract Number: 1651 • 2016 ACR/ARHP Annual Meeting
A Case Series on Patients on Tofacitinib in Combination with a Biologic
Nashla Barroso¹ and Daniel E. Furst², ¹Rheumatology, UCLA David Geffen School of Medicine, Los Angeles, CA, ²David Geffen School of Medicine at UCLA, Los Angeles, CA
Background/Purpose: Although there have been significant advances in the treatment of rheumatoid arthritis (RA) and psoriatic arthritis (PsA). patients can experience a lack of or…
Abstract Number: 1734 • 2016 ACR/ARHP Annual Meeting
Apremilast Is Associated with Long-Term DAS-28 (CRP) Remission and Improvements in Skin Disease: Results from a Phase III Study in DMARD/Biologic-Experienced Active Psoriatic Arthritis Patients
Christopher J Edwards¹, Francisco J Blanco², Jeffrey J Crowley³, Melissa McIlraith⁴, Kamal Shah⁴, Nikolay Delev⁴, Lichen Teng⁴ and Charles A Birbara⁵, ¹University Hospital Southampton, Southampton, United Kingdom, ²INIBIC-Hospital Universitario A Coruña, Galicia, Spain, ³Bakersfield Dermatology, Bakersfield, CA, ⁴Celgene Corporation, Summit, NJ, ⁵University of Massachusetts Medical School, Worcester, MA
Background/Purpose: Treatment goals for long-term control of skin and joint symptoms in active psoriatic arthritis (PsA) include clinically important changes in DAS-28 (CRP), achievement of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].